key: cord-1047160-tn4fig0v authors: Joshi, Rakesh S.; Jagdale, Shounak S.; Bansode, Sneha B.; Shankar, S. Shiva; Tellis, Meenakshi B.; Pandya, Vaibhav Kumar; Chugh, Anita; Giri, Ashok P.; Kulkarni, Mahesh J. title: Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease date: 2020-05-05 journal: J Biomol Struct Dyn DOI: 10.1080/07391102.2020.1760137 sha: f2fa05be20200db6b2183b53e77a0d004ef0dc8f doc_id: 1047160 cord_uid: tn4fig0v Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in the current COVID-19 pandemic. Worldwide this disease has infected over 2.5 million individuals with a mortality rate ranging from 5 to 10%. There are several efforts going on in the drug discovery to control the SARS-CoV-2 viral infection. The main protease (M(Pro)) plays a critical role in viral replication and maturation, thus can serve as the primary drug target. To understand the structural evolution of M(Pro), we have performed phylogenetic and Sequence Similarity Network analysis, that depicted divergence of Coronaviridae M(Pro) in five clusters specific to viral hosts. This clustering was corroborated with the comparison of M(Pro) structures. Furthermore, it has been observed that backbone and binding site conformations are conserved despite variation in some of the residues. These attributes can be exploited to repurpose available viral protease inhibitors against SARS-CoV-2 M(Pro). In agreement with this, we performed screening of ∼7100 molecules including active ingredients present in the Ayurvedic anti-tussive medicines, anti-viral phytochemicals and synthetic anti-virals against SARS-CoV-2 M(Pro) as the primary target. We identified several natural molecules like δ-viniferin, myricitrin, taiwanhomoflavone A, lactucopicrin 15-oxalate, nympholide A, afzelin, biorobin, hesperidin and phyllaemblicin B that strongly binds to SARS-CoV-2 M(Pro). Intrestingly, these molecules also showed strong binding with other potential targets of SARS-CoV-2 infection like viral receptor human angiotensin-converting enzyme 2 (hACE-2) and RNA dependent RNA polymerase (RdRp). We anticipate that our approach for identification of multi-target-directed ligand will provide new avenues for drug discovery against SARS-CoV-2 infection. Communicated by Ramaswamy H. Sarma Coronaviruses, a large family of viruses, causing upperrespiratory-tract infections in humans and other higher mammals (Bedford et al., 2020) . Coronavirus outbreak has been reported three times in the 21st century namely SARS in 2002, MERS in 2012, and COVID-19 in November 2019. The recent outbreak of COVID-19 caused by SARS-CoV-2 has emerged from China. Human-human transmission of this highly infectious zoonotic virus has led to exponential growth in the number of infected cases, which resulted in its pandemic outbreak worldwide (Fahmi, 2020) . Currently, more than 225 countries are affected due to COVID-19 with more than 2.5 million people to date which is increasing in thousands per day around the world and approximately 5 to 10% mortality rate (Fahmi, 2020) . Additionally, the lives of millions of people have been impacted due to mandatory lockdowns, isolations, and quarantines. Thus the severe effect of the COVID-19 outbreak has imposed major challenges for global health, society and economy (Fry, 2020) . Currently, there are no specific antiviral drugs or vaccines available for the treatment and management of COVID-19, which is further making the situation difficult to handle. At present preventive and supportive therapies are being implemented to prevent complications (Salata et al., 2020) . Several efforts are going on to target key proteins of SARS-CoV-2 pathogenesis like the main protease (M Pro ), RNA-dependent RNA polymerase (RdRp), RNA binding N terminal domain (NTD) of Nucleocapsid protein (N protein), viral ion channel (E protein), 2 0 -O-RiboseMethyltransferase and human Angiotensinconverting-enzyme 2 receptor (hACE-2) Gupta et al., 2020; Khan et al., 2020; Sarma et al., 2020; Shang et al., 2020; Zhang et al., 2020) . To propose or repurpose drug and/or lead molecules against SARS-CoV-2, it would be effective to target multiple virus pathogenesis specific proteins within a close network of interaction or having dependent functionality (Zhou et al., 2020) . For drug discovery purposes, the M Pro of coronaviruses has been studied extensively. They are papain-like proteases involved in the self-maturation and processing of viral replicase enzymes . M Pro has 11 putative cleavage sites in 790 kD replicase lab indicating its predominance in the proteolytic processing of large polyprotein lab. M Pro from SARS-CoV-2 showed high sequence identity and structural similarity to that of the SARS-CoV M Pro . It contains two catalytic domains, I (chymotrypsin) and II (picornavirus 3 C protease-like) each containing six-stranded antiparallel b-barrel containing active diad H41 and C145. Since they have a key role in virus replication, these proteases have emerged as important drug targets. Furthermore, with their very low similarity with human proteases, inhibitors of M Pro are found to be very less cytotoxic (Anand et al., 2003; Zhang et al., 2020) . Preliminary studies have suggested the potential use of protease inhibitor lopinavir/ritonavir, commonly used drugs for human immunodeficiency virus (HIV), for the treatment of COVID-19 patients Muralidharan et al., 2020) . Unfortunately, in the open-label randomized clinical study, these drugs are not found to be that impressive for COVID-19 treatment. Additionally, several other viral protease inhibitors like HCV Protease Inhibitor Danoprevir, HIV protease inhibitor Darunavir are under in vivo and clinical studies for the treatment of SARS-CoV-2 infection (Dong et al., 2020) . To find new or repositioning existing drug molecules, the understanding of sequence and structure of SARS-CoV-M Pro in regards to various other coronavirus strains could be important. Their comparative understanding is enigmatic, which could be important to repurpose available antiviral protease inhibitors against SARS-CoV-2 M Pro . Coronavirus uses a multiprotein complex to replicate its RNA based genomes. Cleavage of viral polyproteins (ORF1a and ORF1b) produces a set of non-structural proteins (Nsp). Of these, RdRp or Nsp12 catalyzes the synthesis and is known to play an important role in the replication and transcription cycle of the virus. RdRp is a primary target for nucleotide analog antiviral inhibitors such as Remdesivir, a drug under evaluation for SARS-CoV2 infection in clinics Imbert et al., 2006) . Remdesivir, a nucleotide analog, has shown broad-spectrum antiviral activities, and preclinical studies have also shown promising human safety data (Amirian & Levy, 2020; Dong et al., 2020) . Recently, a report suggested that the significant inhibition of RdRp of SARS-CoV-2 by Remdesivir, and clinical studies for the same are ongoing to evaluate the efficacy of this molecule in the COVID-19 patients (www.clinicaltrials.gov; Study No: NCT04280705) . Apart from the maturation and replication, the entry of this virus by binding its surface spike protein to the hACE-2 is also a crucial process that can be targeted (Hasan et al., 2020; Kuhn et al., 2004; Shang et al., 2020) . Since this host cell receptor is essential for the virus entry; targeting hACE-2 has a promise for preventing SARS-Cov-2 infection. It has been shown that clinically approved serine protease inhibitor (TMPRSS2) can also bind to the SARS-CoV-2 receptor hACE-2 and inhibit viral entry (Hoffmann et al., 2020) . To date, the Chinese Clinical Trial Registry has recorded around 550 trials against SARS-CoV-2, mostly evaluating existing drug molecules. These trials include the application of antiviral (favipiravir, adalimumab, dihydroartemisininpiperaquine, leflunomide, lopinavir), antimalarial drugs (chloroquine or hydroxychloroquine), high-dose vitamin C, etc (www.chictr. org.cn/index.aspx). From the available data of experimental and clinical studies, it has been found that molecules targeting single protein will be ineffective antiviral lead. Thus, to devise an effective strategy, there is a need for molecules that can target multiple key proteins such as RdRp and hACE-2 along with the M Pro as a major drug target . In silico screening of the drugs is a very vital and useful tool for rapid screening. This enables to shortlist leads and thus meet the urgent demand for repurposing drugs for the treatment of SARS-CoV-2 infection. Therefore, in this study, we have performed a comparative analysis of the major target of SARS-CoV-2, M Pro for its structural characteristics to other viruses from the Coronoviridea family. This information was further used for the virtual screening of the custommade library of phytochemicals, active ingredients present in the commonly used ayurvedic anti-tussive medicines in India, and the synthetic anti-viral drugs against M Pro . Top hit molecules from this screen were then docked against SARS-CoV-2 RdRP and hACE2 to find the multi-target-directed molecules. We believe that this study will provide a new approach and a base for the discovery of multi-targeted antiviral molecules against SARS-CoV-2 pathogenesis. Thus these compounds could be potential candidates for in vitro and in vivo antiviral studies followed by clinical treatment of SARS-CoV-2. 2.1. Main protease shows divergence due to sequence variation Phylogenetic analysis of proteases (M Pro ) helped to understand the structural-functional variation of SARS-CoV-2 concerning other viruses from the Coronaviridae family ( Figure 1A ). This analysis suggested that the M Pro 's from the Coronaviridae family are distributed in five clusters. It has been observed that these proteases are separated in different clades depending on their zoonotic sources. In the clade 1 (orange colour), which appears to be the ancestral clade in the phylogenetic tree have sequences from Porcine transmissible gastroenteritis and pandemic diarrhea coronavirus. This clade appears to be evolutionary primitive to avian coronavirus but also showed coevolutionary traits. In the clade 2 (cyan), most of the sequences are from the strains of Avian infectious bronchitis virus. It is then followed by clade 3 (blue), which mainly consists of the sequences from different strains of Bat coronavirus. It is also found to be the parental clade for the clade 4 (red) and the clade 5 (green), which consist of predominantly mammalian host coronaviruses. It is interesting to see that the clade 4, which comprises viruses from bats and the majority of human infectious coronaviruses like SARS, MERS and also recent SARS-CoV-2. Our phylogenetic analysis revalidated the bat origin of the SARS-CoV-2 (Andersen et al., 2020) . While the clade 5 has sequences from Bovine coronaviruses, it also has subclades that are indicative of a distinct host range. Part of the Clade 5 is from the bovine coronavirus and the other part is from murine coronavirus. Between these two subclades, there is a set of sequences that forms clad 5.2 comprises of human coronaviruses like strain OC43 (P0C6U7) and HKU1 (P0C6X3) which have bovine or murine as primary or intermediate host ( Figure 1A ). As evident in the multiple sequence alignment (Supplementary Figure 1) , the M Pro sequences from various coronaviruses strains showed very high conservation in the active site. Also, sequences of M Pro from isolates of SARS-CoV-2 viral strain showed high identity. However, the sequence variation around the active site can lead to the separation of these proteases in distinct clades depending on their hosts. Furthermore, the sequence similarity network (SSN) analysis was carried out to understand the similarities in M Pro sequences from viruses of the Coronaviridae family. It was noted that till e-value 1E-80, all the sequences were clustered together suggesting an extremely high sequence similarity amongst all the Coronaviridae proteases (Supplementary Figure 2) . At e-value 1E-140, the sequences were segregated in 5 clusters ( Figure 1B) . The largest cluster (green) consisted of sequences from bovine coronavirus, murine coronavirus and some human coronavirus such as OC43 and HKU1. The second cluster (orange) exclusively consisted of the porcine coronaviruses and related strains. Bat coronaviruses were grouped in a single cluster (blue), while cyan cluster housed avian coronaviruses. The red cluster consisted of human coronaviruses including SARS, MERS, SARS-CoV-2 along with various other bat coronaviruses. The small cluster of 2 sequences that separated from the red cluster at e-value 1E-125 also belongs to the bat coronaviruses. The clusters of SSN are showing a high correlation with the clades of the phylogenetic tree ( Figure 1A ) suggesting high evolutionary divergence amongst the coronaviruses depending on their host reservoir. This high specificity of the variations related to the host might have resulted from the natural selection in the animal hosts before human transmission (Andersen et al., 2020) . A comparison of 49 structures of M Pro from different coronavirus strains using the DALI server showed five clusters similar to the phylogenetic tree ( Figure 2A ; Supplementary Data 1). Clusters 1 to 3 contains protease structures from porcine transmissible gastroenteritis and pandemic diarrhea coronavirus. Also, they include the M Pro structure from human coronavirus strains like NL63 and HUK. Furthermore, clusters 4 and 5 mostly consist of protease structures from the coronavirus strains causing respiratory infections like SARS, MERS and SARS-CoV-2. The structural similarity matrix with hierarchical clustering also corroborates with the phylogenetic tree and structural cladogram showing the classification of M Pro in five major clusters ( Figure 2B ). These results indicate that sequence variations in the M Pro are also reflected in the structural variations resulting in similar clustering at the sequence and structure level. Structural superimposition of representative proteases from each cluster of the structure cladogram and the similarity matrix depicted that the backbone of these proteases is Figure 1A and B), similar to that observed in phylogenetic analysis, indicating that the sequence variations also depict in the structural analysis of proteases. (C) Structural superimposition of selected proteases from Coronaviridae family, showed RMSD <1Å and the high conservation of the backbone structure (D) Superimposition of the active site and binding site residues displayed conservation of active site pocket shape despite few differences in the residues. This indicated that the substrate recognition and binding efficiency or function of the M Pro are conserved across the virus family. conserved with RMSD less than 1 Å in the majority of cases ( Figure 2C ). It suggests that the sequence variation leads to minor structural changes without major changes in the conformation. Furthermore, a comparison of the substrate-binding pocket of these selected proteases shows that active site residue conformation is highly conserved ( Figure 2D ). There are some variations in the binding pocket residues as shown in the multiple sequence alignment, but these variations are subtle, and overall binding pocket conformation is conserved. Structural conservation of backbone and binding pocket of M Pro from various coronavirus strains suggest that substrate recognition and inhibitor binding would more or less likely to be similar in them. Hegyi and Ziebuhr (2002) have shown the conservation in the substrate specificities and proteolytic processing of replicase polyproteins in the main proteases across coronaviruses (Hegyi & Ziebuhr, 2002) . This similarity highlights the development of universal M Pro assays and the design of broad-spectrum inhibitors of M Pro from different coronavirus strains. This also suggests that the M Pro inhibitor-based drug repositioning would be the rapid and near to accurate approach to screen the drugs against SARS-CoV-2 infection. Besides structural conservation, it is important to understand inter-secondary elements and inter-residue contacts within the protein to unravel the mechanism of these proteases. Secondary structure topology indicates that proteins are asymmetrically populated by the beta-sheets at the N-terminus and helix at C-terminus ( Figure 3A ). The chord plot between pairs of secondary structural elements (arc of a circle) displays the number of interactions (chord thickness) between the corresponding elements. In M Pro , the contacts between the secondary structural elements indicated that the majority of contacts are present in the N-terminus betasheets, which makes the juxtaposed beta barrels connected with the loop that harbors substrate binding site. Whereas, C-terminus globular cluster of helix showed comparatively less number of contacts indicating the rigid nature of these helix cluster involved in the protease dimerization ( Figure 3B ). Inter-residue contact map showed that the population of inter-residue contact is far denser in the first 200 amino acids, which consist of beta barrels having the catalytic role. While C-terminus residues show less We observed that beta-sheets exhibit more contacts than helices (C) Inter-residue contact map within the M Pro . It shows the presence of more interactions in the first 200 residues i.e. towards N-terminus that mainly forms active sites (D) Superimposed topology with colours corresponding to secondary structure elements (E) Root Means Square Fluctuations of the residues from its mean position. High fluctuation (1 Å